Nektar Therapeutics Valuation
| NKTR Stock | USD 0.86 0.01 1.15% |
Today, the firm appears to be undervalued. Nektar Therapeutics secures a last-minute Real Value of $1.76 per share. The latest price of the firm is $0.86. Our model forecasts the value of Nektar Therapeutics from analyzing the firm fundamentals such as Profit Margin of (1.21) %, current valuation of 9.86 M, and Return On Equity of -1.24 as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Nektar Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Nektar Therapeutics is based on 3 months time horizon. Increasing Nektar Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Nektar stock is determined by what a typical buyer is willing to pay for full or partial control of Nektar Therapeutics. Since Nektar Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Nektar Stock. However, Nektar Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.86 | Real 1.76 | Hype 0.86 | Naive 0.92 |
The intrinsic value of Nektar Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nektar Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Nektar Therapeutics helps investors to forecast how Nektar stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nektar Therapeutics more accurately as focusing exclusively on Nektar Therapeutics' fundamentals will not take into account other important factors: Nektar Therapeutics Total Value Analysis
Nektar Therapeutics is now anticipated to have valuation of 9.86 M with market capitalization of 162.52 M, debt of 102.56 M, and cash on hands of 546.39 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Nektar Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.86 M | 162.52 M | 102.56 M | 546.39 M |
Nektar Therapeutics Investor Information
About 72.0% of the company shares are owned by institutional investors. The book value of Nektar Therapeutics was now reported as 0.33. The company recorded a loss per share of 0.58. Nektar Therapeutics had not issued any dividends in recent years. The entity had 2:1 split on the 23rd of August 2000. Based on the key indicators related to Nektar Therapeutics' liquidity, profitability, solvency, and operating efficiency, Nektar Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Nektar Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Nektar Therapeutics has an asset utilization ratio of 32.39 percent. This connotes that the Company is making $0.32 for each dollar of assets. An increasing asset utilization means that Nektar Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Nektar Therapeutics Ownership Allocation
Nektar Therapeutics maintains a total of 186.1 Million outstanding shares. The majority of Nektar Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Nektar Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Nektar Therapeutics. Please pay attention to any change in the institutional holdings of Nektar Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Nektar Therapeutics Profitability Analysis
The company reported the previous year's revenue of 98.43 M. Net Loss for the year was (118.96 M) with profit before overhead, payroll, taxes, and interest of 67.74 M.About Nektar Therapeutics Valuation
The stock valuation mechanism determines Nektar Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Nektar Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Nektar Therapeutics. We calculate exposure to Nektar Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Nektar Therapeutics's related companies.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California. Nektar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 740 people.
Nektar Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Nektar Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 205.7 M |
Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.